The Immunoprotease-Mucin Axis: Senescent Neutrophil-Derived MMP-9 Drives Gut Barrier Failure and Excludes Akkermansia muciniphila in Aging

Thomas Ito· Mar 24, 2026

Mechanism: In aged guts, senescent neutrophils release MMP-9, which degrades mucin O-glycans, disrupting the mucus barrier and excluding Akkermansia muciniphila. Readout: Readout: MMP-9 inhibition restores mucin integrity, increases Akkermansia abundance by 80%, and normalizes inflammation scores.

Hypothesis

Senescent neutrophils in the aged intestine release matrix metalloproteinase‑9 (MMP‑9) that selectively degrades the O‑glycan rich mucin domains, truncating glycan chains and exposing the protein core to bacterial proteases. This enzymatic remodeling creates a mucus environment that is permissive for pathobionts but hostile to the mucin‑specialist Akkermansia muciniphila, whose colonization depends on intact O‑glycan structures for binding and nutrient acquisition. Consequently, the immune system actively drives the loss of its own beneficial symbiont, establishing a feed‑forward loop of barrier decline, inflammaging, and further immune senescence.

Mechanistic Rationale

Mucin O‑glycans as Akkermansia ligands: A. muciniphila utilizes mucin O‑glycans as both carbon source and adhesion receptors; structural studies show that specific GalNAc‑O‑serine/threonine motifs are required for efficient binding [6]
Senescent neutrophil secretory profile: Aging is associated with accumulation of senescent neutrophils that exhibit a senescence‑associated secretory phenotype (SASP) rich in MMP‑9, elastase, and cathepsin G [3]
MMP‑9 mucinolytic activity: MMP‑9 cleaves the peptide backbone of Muc2 upstream of O‑glycosylation sites, leading to loss of glycan chains and increased susceptibility to bacterial sialidases and proteases [1]
Feedback to immune dysregulation: Truncated mucins expose underlying epitopes that stimulate TLR2/4 signaling, amplifying NF‑κB driven IL‑6 production and further neutrophil senescence [2]

Testable Predictions

Elevated mucosal MMP‑9 activity in colonic lavage from aged (24‑month) mice versus young (3‑month) controls, correlating with reduced Muc2 O‑glycan density (detected by lectin staining) and lower A. muciniphila abundance (16S qPCR).
Genetic or pharmacologic ablation of MMP‑9 in aged mice (Mmp9^−/−^ or SB‑3CT treatment) will preserve mucin O‑glycan structure, increase goblet cell Muc2 expression, and restore A. muciniphila colonization to levels seen in young mice, without altering total bacterial load.
Exogenous MMP‑9 administered intrarectally to young mice will recapitulate the aging mucus phenotype: shortened O‑glycan chains, increased permeability (FITC‑dextran assay), decreased A. muciniphila relative abundance, and heightened colonic IL‑6 and TNF‑α.
Adoptive transfer of senescent neutrophils (sorted Ly6G^+^CD62L^low^ from aged donors) into young germ‑free mice will transmit the mucus defect and A. muciniphila depletion, an effect blocked by co‑administration of an MMP‑9 inhibitor.

Falsifiability

If MMP‑9 activity is not increased in the aged gut, or if its inhibition fails to rescue mucin O‑glycan integrity and A. muciniphila colonization despite reducing neutrophil numbers, the hypothesis would be refuted. Likewise, if exogenous MMP‑9 does not impair mucus barrier function or Akkermansia levels, the proposed mucinolytic mechanism would be unsupported.

Potential Impact

Demonstrating that a specific immune‑derived protease sculpts the mucin niche shifts the therapeutic focus from broad anti‑inflammatory strategies to targeted modulation of senescence‑associated secretomes. MMP‑9 inhibition (already explored in fibrosis and cancer) could be repurposed to rejuvenate the intestinal barrier, promote endogenous Akkermansia residency, and thereby attenuate inflammaging‑driven systemic decline.

References (inline)

[1] https://pubmed.ncbi.nlm.nih.gov/30723224/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC6408808/ [3] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1690018/full [4] https://pubmed.ncbi.nlm.nih.gov/3340826/ [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC1379398/ [6] https://pmc.ncbi.nlm.nih.gov/articles/PMC10145456/ [7] https://pubmed.ncbi.nlm.nih.gov/37254162/

Hypothesis

Mechanistic Rationale

Mucin O‑glycans as Akkermansia ligands: A. muciniphila utilizes mucin O‑glycans as both carbon source and adhesion receptors; structural studies show that specific GalNAc‑O‑serine/threonine motifs are required for efficient binding [6]

Senescent neutrophil secretory profile: Aging is associated with accumulation of senescent neutrophils that exhibit a senescence‑associated secretory phenotype (SASP) rich in MMP‑9, elastase, and cathepsin G [3]

MMP‑9 mucinolytic activity: MMP‑9 cleaves the peptide backbone of Muc2 upstream of O‑glycosylation sites, leading to loss of glycan chains and increased susceptibility to bacterial sialidases and proteases [1]

Feedback to immune dysregulation: Truncated mucins expose underlying epitopes that stimulate TLR2/4 signaling, amplifying NF‑κB driven IL‑6 production and further neutrophil senescence [2]

Testable Predictions

Elevated mucosal MMP‑9 activity in colonic lavage from aged (24‑month) mice versus young (3‑month) controls, correlating with reduced Muc2 O‑glycan density (detected by lectin staining) and lower A. muciniphila abundance (16S qPCR).

Genetic or pharmacologic ablation of MMP‑9 in aged mice (Mmp9^−/−^ or SB‑3CT treatment) will preserve mucin O‑glycan structure, increase goblet cell Muc2 expression, and restore A. muciniphila colonization to levels seen in young mice, without altering total bacterial load.

Exogenous MMP‑9 administered intrarectally to young mice will recapitulate the aging mucus phenotype: shortened O‑glycan chains, increased permeability (FITC‑dextran assay), decreased A. muciniphila relative abundance, and heightened colonic IL‑6 and TNF‑α.

Adoptive transfer of senescent neutrophils (sorted Ly6G^+^CD62L^low^ from aged donors) into young germ‑free mice will transmit the mucus defect and A. muciniphila depletion, an effect blocked by co‑administration of an MMP‑9 inhibitor.

Falsifiability

Potential Impact